GB202017251D0 - Neurodegenerative treatment - Google Patents

Neurodegenerative treatment

Info

Publication number
GB202017251D0
GB202017251D0 GBGB2017251.6A GB202017251A GB202017251D0 GB 202017251 D0 GB202017251 D0 GB 202017251D0 GB 202017251 A GB202017251 A GB 202017251A GB 202017251 D0 GB202017251 D0 GB 202017251D0
Authority
GB
United Kingdom
Prior art keywords
neurodegenerative
treatment
neurodegenerative treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2017251.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University of Belfast
Ulster University
Original Assignee
Queens University of Belfast
Ulster University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queens University of Belfast, Ulster University filed Critical Queens University of Belfast
Priority to GBGB2017251.6A priority Critical patent/GB202017251D0/en
Publication of GB202017251D0 publication Critical patent/GB202017251D0/en
Priority to PCT/GB2021/052817 priority patent/WO2022090734A1/en
Priority to EP21806022.6A priority patent/EP4237454A1/en
Priority to US18/141,286 priority patent/US20240082292A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0057—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Xylans, i.e. xylosaccharide, e.g. arabinoxylan, arabinofuronan, pentosans; (beta-1,3)(beta-1,4)-D-Xylans, e.g. rhodymenans; Hemicellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2017251.6A 2020-10-30 2020-10-30 Neurodegenerative treatment Ceased GB202017251D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GBGB2017251.6A GB202017251D0 (en) 2020-10-30 2020-10-30 Neurodegenerative treatment
PCT/GB2021/052817 WO2022090734A1 (en) 2020-10-30 2021-10-29 Neurodegenerative treatment
EP21806022.6A EP4237454A1 (en) 2020-10-30 2021-10-29 Neurodegenerative treatment
US18/141,286 US20240082292A1 (en) 2020-10-30 2023-04-28 Neurodegenerative treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2017251.6A GB202017251D0 (en) 2020-10-30 2020-10-30 Neurodegenerative treatment

Publications (1)

Publication Number Publication Date
GB202017251D0 true GB202017251D0 (en) 2020-12-16

Family

ID=73776477

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2017251.6A Ceased GB202017251D0 (en) 2020-10-30 2020-10-30 Neurodegenerative treatment

Country Status (3)

Country Link
EP (1) EP4237454A1 (en)
GB (1) GB202017251D0 (en)
WO (1) WO2022090734A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US108A (en) 1836-12-15 Braving
US4356A (en) 1846-01-15 A horace h
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150368372A1 (en) * 2014-06-24 2015-12-24 The United States Of America, As Represented By The Secretary Of Agriculture Cellulosic Arabinoxylan fiber (CAF) And Methods Of Preparing

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US108A (en) 1836-12-15 Braving
US4356A (en) 1846-01-15 A horace h
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy", vol. 99, 2000, MACK PUBLISHING CO., article "Protein Composition and Delivery"
J. PHARM. SCI., vol. 66, 1977

Also Published As

Publication number Publication date
WO2022090734A1 (en) 2022-05-05
EP4237454A1 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
GB202108224D0 (en) Treatment
GB201913515D0 (en) Influent treatment improvement
GB202116743D0 (en) Treatment
GB202103122D0 (en) Treatment
GB202016058D0 (en) Therapeautic treatment
GB202003722D0 (en) Treatment
GB202002711D0 (en) Treatment
GB202017251D0 (en) Neurodegenerative treatment
IL312981A (en) Treatment
GB202114373D0 (en) Treatment
GB202109812D0 (en) Treatment
GB202109815D0 (en) Treatment
GB202104666D0 (en) COVID-19 treatment
GB202104416D0 (en) Treatment reginmens
GB202103957D0 (en) Treatment
GB202102488D0 (en) Treatment
GB202102410D0 (en) Treatment
GB202102373D0 (en) Treatment
GB202102369D0 (en) Treatment
GB202102366D0 (en) Treatment
GB202101875D0 (en) Treatment
GB202101897D0 (en) Treatment
GB202101213D0 (en) Treatment
GB202101212D0 (en) Treatment
GB202101211D0 (en) Treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)